FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975192730> ?p ?o ?g. }

• W2975192730 endingPage "1064" @default.
• W2975192730 startingPage "1059" @default.
• W2975192730 abstract "This retrospective study evaluated the outcomes of dogs with macroscopic pulmonary metastasis of appendicular osteosarcoma (OSA) treated with toceranib. Medical records of 20 dogs with macroscopic pulmonary metastasis of OSA that received toceranib were reviewed. The median dose and duration of toceranib administration were 2.52 mg/kg (range: 2.12 to 2.72 mg/kg) and 60 days (range: 17 to 231 days). The median progression free survival (PFS) and overall survival (OS) were 36 days (range: 17 to 231 days) and 90 days (range: 17 to 433 days), respectively. The clinical benefit rate was 10% (2/20; 1 partial response and 1 stable disease). The longest length of initial pulmonary nodules had significant impact on both PFS (P = 0.01) and OS (P = 0.02). The prognosis for dogs with metastatic OSA was poor with only 10% of dogs showing clinical benefit from toceranib. These results suggest that toceranib may not improve outcome in dogs with macroscopic pulmonary metastasis of OSA.Évaluation rétrospective du traitement avec tocéranib (Palladia) pour l’ostéosarcome appendiculaire métastatique canin. Cette étude rétrospective a évalué les résultats des chiens souffrant de métastase pulmonaire macroscopique de l’ostéosarcome appendiculaire (OSE) traité avec tocéranib. Les dossiers médicaux de 20 chiens atteints de métastase pulmonaire macroscopique d’OSE qui ont reçu tocéranib ont été évalués. La dose médiane et la durée de l’administration de tocéranib étaient de 2,52 mg/kg (étendue de 2,12 à 2,72 mg/kg) et de 60 jours (étendue de 17 à 231 jours). La progression de survie libre (PSL) médiane et la survie totale (ST) étaient de 36 jours (étendue de 17 à 231 jours) et de 90 jours (étendue de 17 à 433 jours), respectivement. Le taux de bienfaits cliniques étaient de 10 % (2/20; 1 réponse partielle et 1 maladie stable). Le plus long intervalle avant l’apparition des nodules pulmonaires initiaux avait un impact important sur la PSL (P = 0,01) et la ST (P = 0,02). Le pronostic pour les chiens atteints d’OSE métastatique était mauvais et seulement 10 % des chiens ont manifesté des bienfaits cliniques lors de l’usage de tocéranib. Ces résultats suggèrent que le tocéranib pourraient ne pas améliorer les résultats cliniques chez les chiens souffrant de métastase pulmonaire macroscopique causée par OSE.(Traduit par Isabelle Vallières)." @default.
• W2975192730 created "2019-10-03" @default.
• W2975192730 creator A5046426757 @default.
• W2975192730 creator A5047857657 @default.
• W2975192730 creator A5083656481 @default.
• W2975192730 creator A5088108746 @default.
• W2975192730 date "2017-10-01" @default.
• W2975192730 modified "2023-09-23" @default.
• W2975192730 title "Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma." @default.
• W2975192730 cites W1465731743 @default.
• W2975192730 cites W1485875137 @default.
• W2975192730 cites W1513821330 @default.
• W2975192730 cites W1519934593 @default.
• W2975192730 cites W1540759505 @default.
• W2975192730 cites W15820283 @default.
• W2975192730 cites W1873903910 @default.
• W2975192730 cites W1975294927 @default.
• W2975192730 cites W1983727197 @default.
• W2975192730 cites W1992112921 @default.
• W2975192730 cites W1993488053 @default.
• W2975192730 cites W1997278471 @default.
• W2975192730 cites W2001188898 @default.
• W2975192730 cites W2004254194 @default.
• W2975192730 cites W2019607817 @default.
• W2975192730 cites W2032893940 @default.
• W2975192730 cites W2052275814 @default.
• W2975192730 cites W2053704719 @default.
• W2975192730 cites W2062718932 @default.
• W2975192730 cites W2074196937 @default.
• W2975192730 cites W2086619383 @default.
• W2975192730 cites W2091043062 @default.
• W2975192730 cites W2099782905 @default.
• W2975192730 cites W2103369491 @default.
• W2975192730 cites W2109134893 @default.
• W2975192730 cites W2114760884 @default.
• W2975192730 cites W2118472540 @default.
• W2975192730 cites W2123107246 @default.
• W2975192730 cites W2149908540 @default.
• W2975192730 cites W2153533149 @default.
• W2975192730 cites W2158073590 @default.
• W2975192730 cites W2163032846 @default.
• W2975192730 cites W2166624926 @default.
• W2975192730 cites W2167348613 @default.
• W2975192730 cites W2307392202 @default.
• W2975192730 cites W2395453884 @default.
• W2975192730 cites W2403162707 @default.
• W2975192730 cites W4249710322 @default.
• W2975192730 cites W4250428608 @default.
• W2975192730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5603930" @default.
• W2975192730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28966355" @default.
• W2975192730 hasPublicationYear "2017" @default.
• W2975192730 type Work @default.
• W2975192730 sameAs 2975192730 @default.
• W2975192730 citedByCount "11" @default.
• W2975192730 countsByYear W29751927302018 @default.
• W2975192730 countsByYear W29751927302019 @default.
• W2975192730 countsByYear W29751927302020 @default.
• W2975192730 countsByYear W29751927302021 @default.
• W2975192730 countsByYear W29751927302022 @default.
• W2975192730 countsByYear W29751927302023 @default.
• W2975192730 crossrefType "journal-article" @default.
• W2975192730 hasAuthorship W2975192730A5046426757 @default.
• W2975192730 hasAuthorship W2975192730A5047857657 @default.
• W2975192730 hasAuthorship W2975192730A5083656481 @default.
• W2975192730 hasAuthorship W2975192730A5088108746 @default.
• W2975192730 hasConcept C121608353 @default.
• W2975192730 hasConcept C126322002 @default.
• W2975192730 hasConcept C142724271 @default.
• W2975192730 hasConcept C167135981 @default.
• W2975192730 hasConcept C2777760704 @default.
• W2975192730 hasConcept C2779013556 @default.
• W2975192730 hasConcept C3019894029 @default.
• W2975192730 hasConcept C3019926457 @default.
• W2975192730 hasConcept C71924100 @default.
• W2975192730 hasConceptScore W2975192730C121608353 @default.
• W2975192730 hasConceptScore W2975192730C126322002 @default.
• W2975192730 hasConceptScore W2975192730C142724271 @default.
• W2975192730 hasConceptScore W2975192730C167135981 @default.
• W2975192730 hasConceptScore W2975192730C2777760704 @default.
• W2975192730 hasConceptScore W2975192730C2779013556 @default.
• W2975192730 hasConceptScore W2975192730C3019894029 @default.
• W2975192730 hasConceptScore W2975192730C3019926457 @default.
• W2975192730 hasConceptScore W2975192730C71924100 @default.
• W2975192730 hasIssue "10" @default.
• W2975192730 hasLocation W29751927301 @default.
• W2975192730 hasOpenAccess W2975192730 @default.
• W2975192730 hasPrimaryLocation W29751927301 @default.
• W2975192730 hasRelatedWork W1896072691 @default.
• W2975192730 hasRelatedWork W1994309660 @default.
• W2975192730 hasRelatedWork W2360863845 @default.
• W2975192730 hasRelatedWork W2463801166 @default.
• W2975192730 hasRelatedWork W2569828025 @default.
• W2975192730 hasRelatedWork W2578939472 @default.
• W2975192730 hasRelatedWork W3150357538 @default.
• W2975192730 hasRelatedWork W4200270905 @default.
• W2975192730 hasRelatedWork W4213040310 @default.
• W2975192730 hasRelatedWork W4220944025 @default.
• W2975192730 hasVolume "58" @default.

• next